about
Ochronosis as an unusual cause of valvular defect: a case reportA 3-year randomized therapeutic trial of nitisinone in alkaptonuriaTreatment of nongout joint deposition diseases: an updateNitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinismPathology of the earAortic stenosis and vascular calcifications in alkaptonuriaMutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria.An update on molecular genetics of Alkaptonuria (AKU).Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.Aortic valve ochronosis: a rare manifestation of alkaptonuriaImpact of chronic kidney disease on the natural history of alkaptonuria.Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition.Alkaptonuria: leading to the treasure in exceptions.Alkaptonuria--a review of surgical and autopsy pathology.A Founder Effect for the HGD G360R Mutation in Italy: Implications for a Regional Screening of Alkaptonuria.Endogenous ochronosis: case report and a systematic review of the literature.Alkaptonuria in France: past experience and lessons for the future.Shoulder arthroplasty in alkaptonuric arthropathy: a clinical case report and literature review.A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione.Alkaptonuria-associated aortic stenosis.Redox proteomics gives insights into the role of oxidative stress in alkaptonuria.Alkaptonuria.Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.Acute fatal metabolic complications in alkaptonuria.Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria.The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing.Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.Alkaptonuria and Pompe disease in one patient: metabolic and molecular analysis.Alkaptonuria.Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury.Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.Alkaptonuric ochronosis: a clinical study from Ardabil, Iran.Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.Alkaptonuria Severity Score Index Revisited: Analysing the AKUSSI and Its Subcomponent Features.
P2860
Q21202101-FA373488-6721-41F2-81D4-7339205622BAQ24624747-4E6C986C-953D-4316-AF41-E86A0B6965D8Q26852957-4E205159-4533-4501-9D3D-15D6E71643C2Q28249590-7A5C7F38-7DFE-44BB-BCD7-180C16123A95Q30462001-0DA48F4F-D853-4A70-8BA8-D922B97D84D4Q30504971-3950FB06-11FE-4791-ADBA-261D5A7DB7C5Q33694024-F82224FD-8FAB-4B7F-89F5-642B3D3C4C77Q34196817-DF920207-D57A-4818-9817-D57AFA82401CQ34560227-9338C791-24DD-42DD-A528-D37A9F71FD24Q34590786-0417BF30-060E-4767-A50B-07BD6FB32078Q35145389-AA26DA6C-F89B-4021-A74A-50E11BE6520AQ35366724-E2BC872C-850F-408B-84E1-2BA91CCAC4E9Q36090590-38D1C4DF-1FAF-4627-97A5-FAF9FB34A2C7Q36120348-B63B7BF9-24F4-428B-B546-9755C9CC8373Q36433474-12E19AEB-9BF3-41E8-AAE9-5A6E83E3F1D6Q37108785-480F40F3-81BD-4695-BCE0-33811BFBA747Q37415880-839F8D95-E4EE-416D-9452-5E1CBB12C089Q37845902-B1754491-64CB-478B-B7B9-C8F08B1D2347Q37934608-8EFD3C66-66AC-49F6-9E02-A0B621C22741Q37996911-833239C3-80A2-48B4-A4E5-F324E8FF571AQ38080895-21327255-19A5-43A7-96C1-56393F8D3F4FQ38123518-28773D6A-739C-4E3A-B3BE-534BD6679234Q38160929-70CA3AA3-0143-4D3B-B5D3-A42CA994BF9FQ38227178-68E13E47-F9B8-47D9-A04E-02985E66B672Q38414587-36E03830-9518-4EB0-A61E-BB7E919B8D51Q38644004-2179D10B-4681-4959-9D7A-8CA4C81F56C1Q38869592-A423BCE7-2D4A-4CD5-8719-51255611E802Q39024172-E2F5DB21-5D5E-46E7-9FFE-A4809FF785BBQ39061550-5A3C6654-E827-4B87-A060-CFDE6BF9AF4EQ39681289-073BFBFF-B0D6-4F3A-86B9-FD8C72E74B49Q39944647-B115B073-3215-4966-8011-E662DF7D4426Q40413861-4D7F244A-51AC-487D-A424-B5FE93D6547AQ42746658-A443288A-C343-45D7-85A0-1C651F5178B7Q42963024-C17F7196-FBA1-4783-B2D0-259FB8D90066Q43123162-2D86A769-B037-497F-AF23-12ACE44558B9Q49935371-87B5127A-A54B-44E6-BE23-760FE8990A42Q50226081-2EDB0155-D03A-4299-AD4D-FECF7E152DBCQ50850348-D09D6A2F-911D-4935-BC38-45F098B14DCAQ52588914-5CCC756A-83C4-4645-B4E9-050D9D397EFC
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Use of nitisinone in patients with alkaptonuria.
@ast
Use of nitisinone in patients with alkaptonuria.
@en
Use of nitisinone in patients with alkaptonuria.
@nl
type
label
Use of nitisinone in patients with alkaptonuria.
@ast
Use of nitisinone in patients with alkaptonuria.
@en
Use of nitisinone in patients with alkaptonuria.
@nl
prefLabel
Use of nitisinone in patients with alkaptonuria.
@ast
Use of nitisinone in patients with alkaptonuria.
@en
Use of nitisinone in patients with alkaptonuria.
@nl
P2093
P1433
P1476
Use of nitisinone in patients with alkaptonuria
@en
P2093
Benjamin I Rubin
Ekaterina Tsilou
Isa Bernardini
Kevin O'Brien
Monique B Perry
Muriel I Kaiser-Kupfer
Nancy Sebring
Pim Suwannarat
William A Gahl
P304
P356
10.1016/J.METABOL.2004.12.017
P577
2005-06-01T00:00:00Z